What Nemera does

Nemera is a France-headquartered, privately held contract development and manufacturing organization (CDMO) specializing in drug delivery device solutions across ophthalmic, parenteral, inhalation, dermal, ear-nose-throat, oral, and intimate care administration routes. The company designs, develops, and manufactures proprietary device platforms — including the Novelia multi-dose eyedropper system with patented PureFlow silicone membrane technology, Safe'n'Sound passive needle safety devices, Symbioze on-body wearable injectors for high-viscosity biologics, Sof'Bag+ airless dermal packaging, and DPI/pMDI inhalers — alongside tailor-made pen injectors and auto-injectors. Manufacturing is conducted across five GMP-certified sites in France, Germany, Poland, the United States, and Brazil, encompassing over 42,000 square meters of clean room capacity and producing more than one billion devices annually for distribution in 54 countries.

The company operates a hybrid B2B business model combining project-based combination product development services (front-end innovation, human factors, design verification, regulatory strategy) with proprietary product sales and contract manufacturing across clinical and commercial volumes. Customers are large pharmaceutical, biotechnology, and generic drug companies — disclosed enterprise relationships include GlaxoSmithKline, SciGen, and Haohai Qisheng. Pricing is negotiated per-project under multi-year contracts and is not publicly disclosed. The Insight Innovation Center in Chicago houses over 200 innovation and device development consultants serving as Nemera's front-end innovation engine.

Nemera is jointly owned by private equity firms Montagu and Astorg (with LGT Capital Partners as a co-investor), and traces its corporate history to Rexam Healthcare before being acquired by Montagu in 2014. The company has pursued a sustained buy-and-build strategy (Insight Product Development in 2019, Copernicus in 2020, Milfra in 2021) and has stated a strategic ambition to become a billion-dollar company by 2030. The company maintains comprehensive quality certifications including ISO 13485, EU MDR, FDA 21 CFR Part 820, MDSAP, and EcoVadis Gold status for sustainability.

Name

Nemera

Legal name

Financiere N

Website

https://nemera.net

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Nemera is a France-headquartered, PE-backed CDMO designing and manufacturing proprietary drug delivery devices — eyedroppers, injectors, inhalers, and nasal systems — for global pharmaceutical, biotech, and generics customers across five manufacturing sites serving 54 countries.

Ownership category

akta.pro rank

Product category

Drug Delivery Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories) (HLAHAGAE)

Keywords

• Drug delivery devices
• Contract manufacturing services
• Combination product development
• Ophthalmic drug delivery
• Parenteral injection devices

Headquarters

HQ city

La Verpillière

HQ country

France

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Nemera provides contract development and manufacturing services for drug delivery devices and combination products. This includes clinical and commercial manufacturing, process engineering, and industrialization services. Revenue is generated through project-based contracts and long-term manufacturing partnerships with pharmaceutical companies.
2. Proprietary Product Sales: Sale of Nemera's own IP products including Novelia eyedroppers, Safe'n'Sound safety systems, pen injectors, pumps, and other drug delivery devices to pharmaceutical customers.
3. Combination Product Development Services: Comprehensive services covering the entire combination product journey including analytical services, design verification, human factors engineering, regulatory strategy, and submission authoring. These services are provided as standalone or integrated packages.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Nemera is a global Contract Development and Manufacturing Organization (CDMO) that designs, develops, and manufactures proprietary drug delivery device solutions — including ophthalmic eyedroppers, pen and auto-injectors, safety syringes, inhalers, nasal pumps, dermal packaging, and wearable injectors — alongside combination product development, clinical and commercial manufacturing, and regulatory services for pharmaceutical, biotechnology, and generic drug customers.

Product overview

Nemera is a global CDMO (Contract Development and Manufacturing Organization) providing holistic drug delivery device solutions and combination product services. The company offers a comprehensive portfolio of proprietary drug delivery devices across multiple therapeutic areas: Ophthalmic (Novelia® and e-Novelia eyedroppers), Dermal (Sof'Bag®+, Sof'Airless XS+, atmospheric pumps, CRC closures), Ear Nose Throat (SP27/SP37 multidose pumps, UniSpray, DuoSpray, DriDose®, Safe'n'Spray electronic devices, nasal vaccine), Inhalation (DPI and pMDI inhalers), and Parenteral (Safe'n'Sound® passive safety systems, reusable/disposable/tailor-made pen injectors, implanters, Symbioze® on-body injector wearables). The company also provides intimate care applicators and oral administration dosers. Nemera operates as an integrated partner offering front-end innovation, device development, clinical/commercial manufacturing, and regulatory strategy services. The product portfolio is supported by manufacturing facilities in France, Germany, Poland, US, and Brazil, with over 200 innovation consultants at Insight Innovation Centers.

Differentiator

Problem solved

Functional benefit

Products and services

• Novelia® multi-dose eyedropper Multi-dose eyedropper with a closing tip system that prevents bacterial contamination and eliminates the need for preservatives in ophthalmic formulations. Features a patented blue tip for enhanced eye targeting and PureFlow® silicone membrane venting technology. Sold to pharmaceutical customers for ophthalmic drug products.
• e-Novelia smart ophthalmic add-on Smart ophthalmic add-on device that improves existing ophthalmic treatment administration to enhance patient adherence. Used by pharmaceutical customers alongside ophthalmic drug products.
• Safe'n'Sound® passive safety device (1ml and 2.25ml) Premium passive safety device platform that prevents needlestick injuries with an ergonomic design for both skilled and inexperienced users, available in 1ml and 2.25ml prefilled syringe configurations. Sold to pharmaceutical customers for injectable drugs.
• Reusable Pen Injectors Reusable pen injector platform with replaceable cartridges for multidose formulation delivery, intended for extended use over several years. Used by pharmaceutical customers for chronic conditions such as diabetes and growth hormone deficiency.
• Disposable Pen Injectors Ready-to-use prefilled disposable pen injectors with a set drug amount in the cartridge, disposed of when depleted. Used by pharmaceutical customers for single-course injectable therapies.
• Tailor-made Pens and Auto-Injectors Custom-designed pen injectors and auto-injectors tailored to customer specifications for pharmaceutical products including insulin, GLP-1, hormones, and fertility treatments.
• Symbioze® on-body wearable injector Unique on-body wearable injector for subcutaneous delivery of high-viscosity biologic formulations, with a robust, easy-to-use design intended for self-administration at home. Sold to biotechnology and pharmaceutical customers developing biologics.
• Implanters with integrated needlestick protection Devices for implant delivery with integrated needlestick protection, designed to support improved holding, priming, and motion for implant insertion by healthcare professionals and patients.
• DPI and pMDI Inhalers Pressurized Metered Dose Inhalers (pMDI) and Dry Powder Inhalers (DPI) for treating asthma and COPD, covering the full development lifecycle from concept to large-scale manufacturing. Sold to pharmaceutical customers in respiratory therapeutics.
• UniSpray single-metered dose nasal device Single-metered accurate dose nasal delivery device ideal for systemic delivery in emergency life-saving and crisis treatment, particularly suitable for naloxone rescue applications.
• DuoSpray nasal delivery device DuoSpray nasal delivery device designed to deliver life-saving and crisis treatments with high efficiency and robustness for nasal drug delivery.
• DriDose® dry powder intranasal platform DriDose® dry powder intranasal delivery technology developed in partnership with Therakind for delivering innovative medicines, particularly life-saving and crisis treatments, via the nasal route.
• SP27 and SP37 Multidose Pump Systems Multidose pump systems for ear, nose and throat delivery, providing a full range of pump and valve platforms ensuring precision and dose consistency for nasal and oral drugs.
• Safe'n'Spray electronic nasal device Electronic nasal drug delivery device with full design, development and manufacturing services for electronic nasal devices. Sold to pharmaceutical customers for nasal drugs requiring electronic delivery control.
• Sof'Bag®+ airless pouch-in-bottle packaging Airless pouch-in-bottle packaging solution for prescription (Rx) and over-the-counter (OTC) dermal and transdermal formulations, protecting sensitive formulations from oxygen, light, and moisture.
• Sof'Airless XS+ mini-airless system Protective mini-airless system for delivering gel and cream formulations in small dose applications and sampling. Used by pharmaceutical and dermocosmetic customers.
• Atmospheric spray pumps for liquid formulations Atmospheric spray pumps for delivering liquid and viscous formulations across comprehensive dose ranges, suitable for regulated and less regulated markets.
• Vaginal and rectal applicators Vaginal and rectal applicators used to treat intimate pathologies including vaginal infections, bacterial vaginosis, vaginal atrophy, hemorrhoids, and anal fissures.
• Liquid oral dosers Liquid delivery dosers for pediatric applications including non-narcotic analgesics, anti-acids, anti-flatulents, and medical food supplementation.
• Front-End Innovation and Device Development services Front-end innovation, human factors research, design engineering, and device development services for pharmaceutical and biotechnology customers, delivered by the Insight by Nemera practice of 200+ consultants. Sold as standalone or integrated packages.
• Clinical and Commercial Manufacturing services Contract development and manufacturing services covering clinical device supply, process engineering and industrialization, and commercial manufacturing for drug delivery devices and combination products, delivered from five global manufacturing facilities.
• Combination Product Services Comprehensive services covering the entire combination product journey including analytical services, design verification, human factors engineering, regulatory strategy, and submission authoring. Provided as standalone or integrated packages to pharmaceutical customers.

Quantifiable outcome

• Over 1 billion devices sold annually across 54 countries
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core.

• TherakindcoreStrategic or Co-development Partner · 1 April 2026Strategic partnership to advance DriDose® dry powder intranasal technology. The partnership combines Nemera's know-how with Therakind's experience in developing and delivering innovative medicines to patients for life-saving and crisis treatments.
• Haohai Qisheng (Shanghai HaoHai)coreOEM/ Whitelabel/ Licensing Partner · 1 January 2026Chinese pharmaceutical company that launched lubricant eyedrops (Eyesucom®) with Nemera's Novelia® 15mL dispenser in China for contact lens discomfort and dry eye treatment. This partnership extends Novelia's global reach to the Chinese market.
• ZollnercoreTechnology or IntegrationPartnership for the development of electronic drug delivery devices. Zollner supports the design, development, and manufacturing of electronic drug delivery systems for both Nemera's proprietary and customer-owned products. Collaboration begins with Nemera's existing electronic device portfolio.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• West Pharmaceutical Services: Global leader in elastomeric components, injectables containment, and drug delivery devices (auto-injectors, prefilled systems). Most direct competitor to Nemera across primary packaging and combination-product device platforms serving the same Big Pharma customer base.
• Ypsomed Holding AG: Swiss specialist in pen injectors, auto-injectors, and large-volume wearable injectors for self-medication. Direct competitor across Nemera's pen and Symbioze wearable portfolios, particularly in diabetes, GLP-1, and biotech injectables.
• Phillips-Medisize (a Molex company): CDMO for medical devices and drug delivery, including injectors, inhalers, and connected health devices. Closely comparable integrated design-to-manufacture offering to Nemera's Insight + manufacturing model.
• Stevanato Group: Italian-headquartered drug containment and delivery solutions provider offering glass vials, syringes, and device platforms including pen injectors and on-body delivery systems. Closest scale and product-mix comparable to Nemera.
• Owen Mumford: UK-based drug delivery device specialist with proprietary auto-injector, pen, and safety platforms sold B2B to pharma. Highly comparable business model and product range to Nemera, particularly in parenteral and self-injection devices.
• Gerresheimer AG: Pharmaceutical packaging and drug delivery device manufacturer with strong positions in prefilled syringes, auto-injectors, and inhalation devices. Directly competes with Nemera in parenteral and combination-product categories.
• Schott Pharma: Primary packaging and drug delivery arm of Schott AG, focused on glass vials, syringes, cartridges and integrated drug containment solutions. Direct competitor to Nemera in pharma primary packaging and combination-product enabling technologies.

Broad incumbents

• Becton, Dickinson and Company (BD): Large diversified medical technology company with broad pharmaceutical systems and drug delivery device franchises (BD Medical). Larger scale and broader portfolio than Nemera, but overlaps meaningfully in prefilled syringes, auto-injectors, and injection safety devices.
• Recipharm (ReciBio): Large pharmaceutical CDMO offering sterile fill-finish, biologics, and advanced delivery services. Overlaps with Nemera in clinical and commercial manufacturing services, though less device-specialized.

Emerging players

• Hovione: CDMO with growing device and inhalation business. Smaller and more drug-substance anchored than Nemera, but increasingly competes in DPI/inhalation device development and aseptic manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCvM61s6alPN62yYqoZlhkHw
• LinkedInlinkedin.com/company/nemera

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nemera